Literature DB >> 22824047

New therapeutic strategy for treating otitis media with effusion in postirradiated nasopharyngeal carcinoma patients.

Chin-Lung Kuo1, Mao-Che Wang, Chia-Huei Chu, An-Suey Shiao.   

Abstract

BACKGROUND: Postirradiation otitis media with effusion (OME) is the most common radiotherapy-associated otologic complication associated with nasopharyngeal carcinoma (NPC). This study's aim was to evaluate the efficacy of laser myringotomy followed by intratympanic steroid injection (LMIS) for treating OME in postirradiated NPC patients.
METHODS: From August 2002 to January 2006, 27 newly diagnosed NPC patients who developed OME after a full course of radiotherapy were enrolled. Laser myringotomy was performed followed by once-weekly administration of steroids (0.5mL dexamethasone at a concentration of 5.0mg/mL) into the middle ear for 3 consecutive weeks. The success rate of dry eardrum perforation and the prognostic factors associated with OME resolution were analyzed.
RESULTS: The procedure was performed on 44 ears of 27 patients. The mean follow-up period was 37 weeks. Of the 44 ears, 23 (52.3%) developed persistent eardrum perforation, 18 (40.9%) developed recurrent OME, and three (6.8%) were disease-free on follow-up. Of the 23 ears with persistent eardrum perforation, 18 (78.3%) were diagnosed as dry perforation. The absence of pretreatment mastoiditis was an independent factor associated with OME resolution (p<0.001).
CONCLUSION: LMIS is a quick, minimally invasive, office-based technique that can be repeatedly performed to treat highly recurrent postirradiation OME, and it results in relatively slight pain to NPC patients. Long-lasting dry eardrum perforation allows for adequate middle ear ventilation and drainage and guarantees sustained relief from symptoms. The absence of preoperative mastoiditis is a favorable prognostic factor associated with OME resolution.
Copyright © 2012. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22824047     DOI: 10.1016/j.jcma.2012.04.016

Source DB:  PubMed          Journal:  J Chin Med Assoc        ISSN: 1726-4901            Impact factor:   2.743


  7 in total

1.  Challenges of Hearing Rehabilitation after Radiation and Chemotherapy.

Authors:  Marc-Elie Nader; Paul W Gidley
Journal:  J Neurol Surg B Skull Base       Date:  2019-02-04

2.  The effectiveness of myringotomy and ventilation tube insertion versus observation in post-radiation otitis media with effusion.

Authors:  Paninee Charusripan; Likhit Khattiyawittayakun
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-05-24       Impact factor: 2.503

3.  Active raster scanning with carbon ions: reirradiation in patients with recurrent skull base chordomas and chondrosarcomas.

Authors:  Matthias Uhl; Thomas Welzel; Jan Oelmann; Gregor Habl; Henrik Hauswald; Alexandra Jensen; Malte Ellerbrock; Jürgen Debus; Klaus Herfarth
Journal:  Strahlenther Onkol       Date:  2014-03-25       Impact factor: 3.621

4.  Dural metastasis of nasopharyngeal carcinoma: rare, but worth considering.

Authors:  Chin-Lung Kuo; Donald Ming-Tak Ho; Ching-Yin Ho
Journal:  Singapore Med J       Date:  2014-05       Impact factor: 1.858

5.  Predictors of Mastoiditis after Intensity-Modulated Radiotherapy in Nasopharyngeal Carcinoma: A Dose-Volume Analysis.

Authors:  Ji-Jin Yao; Guan-Qun Zhou; Ya-Nan Jin; Wang-Jian Zhang; Li Lin; Xiao-Li Yu; Jian-Yong Shao; Jun Ma; Ying Sun
Journal:  J Cancer       Date:  2016-01-08       Impact factor: 4.207

6.  The Efficacy of Adjuvant Intratympanic Steroid Treatment for Otitis Media with Effusion in Children.

Authors:  Hazem Saeed Amer; Mohammad Waheed El-Anwar; Alaa Eldin Elfeky
Journal:  Int Arch Otorhinolaryngol       Date:  2015-09-29

7.  The Efficacy of Nasal Steroids in Treatment of Otitis Media with Effusion: A Comparative Study.

Authors:  Mohammad Waheed El-Anwar; Ahmad Abdel-Fattah Nofal; Alaa Omar Khazbak; Ahmad Ebrahim El Sayed; Mohammad Ramadan Hassan
Journal:  Int Arch Otorhinolaryngol       Date:  2015-03-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.